The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis

Current Osteoporosis Reports

Volumn 12, Issue 1, 2014, Pages 90-97

  Guañabens, Núria ^a   Gifre, Laia ^a   Peris, Pilar ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Dkk 1; Glucocorticoid; Osteoporosis; Sclerostin; Wnt pathway

Indexed keywords

APC PROTEIN; BETA CATENIN; DEXAMETHASONE; DICKKOPF 1 PROTEIN; FOCAL ADHESION KINASE; FRIZZLED PROTEIN; GLUCOCORTICOID; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PREDNISOLONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCLEROSTIN; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; WNT PROTEIN;

BONE MASS; BONE TURNOVER; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ASSOCIATION; DRUG EFFECT; FOLLOW UP; GAIN OF FUNCTION MUTATION; HUMAN; LOSS OF FUNCTION MUTATION; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; PATHOGENESIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION;

BONE DENSITY; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; GLUCOCORTICOIDS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84895925011     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-014-0197-0     Document Type: Review

References (49)

1. Weinstein RS. Glucocorticoid-induced bone disease. In: Rosen CF, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th ed. American Society for Bone and Mineral Research. Iowa, USA: Wiley; 2013. p. 473-81.
2. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319-28. (Pubitemid 47389469)
3. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6:82-8.
4. .• Bultink IEM, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013;14:185-97. This article reviews the current concepts on the pathogenesis and management of glucocorticoid-induced osteoporosis.
5. Bellido T. Antagonistic interplay between mechanical forces and glucocorticoids in bone: a tale of kinases. J Cell Biochem. 2010;111:1-6.
6. Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival: evidence for inside-out signaling leading to anoikis. J Biol Chem. 2007;282:24120-30. (Pubitemid 47328056)
7. Xia X, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, et al. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res. 2010;25:2479-88.
8. Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte viability with glucocorticoid treatment: relation to histomorphometry. Ann Rheum Dis. 2003;62:1215-7. (Pubitemid 37500630)
9. Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45:2163-72.
10. Canalis E. Wnt signaling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013;9:575-83.
11. .•• Baron R, Kneissel M. Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19: 179-92. This article is an extensive review on Wnt signaling in bone homeostasis.
12. Bonewald LF. The amazing osteocyte. J BoneMiner Res. 2011;26: 229-38.
13. Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012;27:499-505.
14. Baron R, Rawadi G. Targeting the Wnt/ß-Catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-43. (Pubitemid 46984775)
15. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754-66.
16. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113:517-25.
17. Voorzaner-Rousselot N, Goehrig D, Facon T, Clézardin P, Garnero P. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol. 2009;145:264-6.
18. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373-9.
19. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2010;26:27-34.
20. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011;26:2812-22.
21. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signaling pathway (Dickkopf-1(DKK1) and sclerostin), bonemineral density, vascular calcification and arterial stiffness in postmenopausal women. Bone. 2013;56:42-7.
22. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D. Circulating sclerostin and dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473-80.
23. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women - the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23:1171-6.
24. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489-94.
25. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95:2248-53.
26. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone. 2012;50:739-42.
27. Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naïve postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab. 2013;98:3206-12.
28. Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res. 2012;27:2259-63.
29. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab. 2011;96:E1848-51.
30. Piemonte S, Romagnoli E, Bratengeier C, Woloszczuk W, Tancredi A, Pepe J, et al. Serum sclerostin levels decline in postmenopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest. 2012;35:866-8.
31. Li C, Xing Q, Yu B, Xie H, Wang W, Shi C, et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J Bone Miner Res. 2013;8:2094-108.
32. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;52:44326-35.
33. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009;379:261-6.
34. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005;329:177-81. (Pubitemid 40255437)
35. Butler JS, Queally JM, Devitt BM, Murray DW, Doran PP, O'Byrne JM. Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord. 2010;11:210.
36. Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int. 2009;85: 538-45.
37. Hurson CJ, Butler JS, Keating DT, Murray DW, Sadlier DM, O'Byrne JM, et al. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet Disord. 2007;8:12.
38. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004;318:259-64. (Pubitemid 38526274)
39. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008;58:1674-86. (Pubitemid 351847520)
40. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology. 2008;149:1793-801.
41. .•• Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res. 2012;27: 2242-50. This article assesses the effect of glucocorticoid treatment in cultures of osteoblasts and osteocytes, as well as in rodents.
42. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum. 2011;63:2385-95.
43. .•• Brabnikova Maresova K, Pavelka K, Stepan JJ. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int. 2013;92:354-61. This article assesses the levels of sclerostin and Dkk-1 in patients with glucocorticoid treatment at short term.
44. .• Gifre L, Ruiz-Gaspà S, Monegal A, Nomdedeu B, Filella X, Guañabens N, et al. Effect of glucocorticoid treatment on Wnt signaling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone. 2013;57:272-6. This article assesses the levels of sclerostin and Dkk-1 in patients with glucocorticoid treatment at short and long term.
45. .• Gossiel F, Lane N, Eastell R. The effect of glucocorticoid therapy on regulators of bone formation in postmenopausal women treated with teriparatide or alendronate. ASBMR Annual Meeting; 2011. p. S80 [Abstract]. This abstract assesses the levels of sclerostin and Dkk-1 in patients with glucocorticoid treatment in the short-term.
46. Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, et al. Serum extracellular secreted antagonists of the canonical Wnt/ β-catenin signaling pathway in patients with Cushing 's syndrome. Osteoporos Int. 2013;24:2191-9.
47. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab. 2012;97:E1953-7.
48. Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gagnon DR, et al. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012;27:352-9.
49. Brunetti G, Faienza MF, Piacente L, Ventura A, Oranger A, Carbone C, et al. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab. 2013;304:E546-54.